NFKB1 and atherosclerosis: Moreover, the inhibitor of DPP-IV sitagliptin also inhibited NF-κB activating AMPK in a model of atherosclerosis in apolipoprotein-E-knockout mice [15] and in rats with streptozotocin-induced diabetes [16].